122 related articles for article (PubMed ID: 32808565)
1. A sustainable UPLC-UV method for quantification of donepezil hydrochloride in biorelevant media applied to dissolution profile comparison.
de Campos DP; Silva-Barcellos NM; Marinho FDM; Barbosa GX; Lana VLVV; de Souza J
Drug Dev Ind Pharm; 2020 Oct; 46(10):1578-1588. PubMed ID: 32808565
[TBL] [Abstract][Full Text] [Related]
2. Chemometrics-assisted spectrophotometric green method for correcting interferences in biowaiver studies: Application to assay and dissolution profiling study of donepezil hydrochloride tablets.
Korany MA; Mahgoub H; Haggag RS; Ragab MAA; Elmallah OA
Spectrochim Acta A Mol Biomol Spectrosc; 2018 Jun; 199():328-339. PubMed ID: 29627618
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of assay and in-vitro dissolution profile of certain fixed-dose combination using green analytical method.
Lotfy HM; Obaydo RH; Sakur AA
Ann Pharm Fr; 2021 Jan; 79(1):3-15. PubMed ID: 32777297
[TBL] [Abstract][Full Text] [Related]
4. Development and Validation of Discriminating and Biorelevant Dissolution Test for Lornoxicam Tablets.
Anumolu PD; Sunitha G; Bindu SH; Satheshbabu PR; Subrahmanyam CV
Indian J Pharm Sci; 2015; 77(3):312-20. PubMed ID: 26180277
[TBL] [Abstract][Full Text] [Related]
5. Prediction of in vivo drug performance using in vitro dissolution coupled with STELLA: a study with selected drug products.
Chakraborty S; Yadav L; Aggarwal D
Drug Dev Ind Pharm; 2015; 41(10):1667-73. PubMed ID: 25494535
[TBL] [Abstract][Full Text] [Related]
6. Validation of Dissolution Testing with Biorelevant Media: An OrBiTo Study.
Mann J; Dressman J; Rosenblatt K; Ashworth L; Muenster U; Frank K; Hutchins P; Williams J; Klumpp L; Wielockx K; Berben P; Augustijns P; Holm R; Hofmann M; Patel S; Beato S; Ojala K; Tomaszewska I; Bruel JL; Butler J
Mol Pharm; 2017 Dec; 14(12):4192-4201. PubMed ID: 28737403
[TBL] [Abstract][Full Text] [Related]
7. Similarity of dissolution profiles from biorelevant media: Assessment of interday repeatability, interanalyst repeatability, and interlaboratory reproducibility using ibuprofen and ketoconazole tablets.
Jamil R; Xu T; Shah HS; Adhikari A; Sardhara R; Nahar K; Morris KR; Polli JE
Eur J Pharm Sci; 2021 Jan; 156():105573. PubMed ID: 32987114
[TBL] [Abstract][Full Text] [Related]
8. Development of a dissolution method for lumefantrine and artemether in immediate release fixed dose artemether/lumefantrine tablets.
Belew S; Suleman S; Duguma M; Teshome H; Wynendaele E; Duchateau L; De Spiegeleer B
Malar J; 2020 Apr; 19(1):139. PubMed ID: 32264882
[TBL] [Abstract][Full Text] [Related]
9. Development of bioanalytical HPLC method for simultaneous determination of the antialzhiemer, donepezil hydrochloride and the antidepressant, citalopram hydrobromide in raw materials, spiked human plasma and tablets dosage form.
Ragab GH; Bahgat EA
Ann Pharm Fr; 2019 Mar; 77(2):112-120. PubMed ID: 30528254
[TBL] [Abstract][Full Text] [Related]
10. Developing a Biorelevant Dissolution Method for an Extrudable Core System (ECS) Osmotic Tablet.
Chen R; Blanchard A; Kushner J; Harrington B; Liu J; DeMatteo V
AAPS PharmSciTech; 2021 Nov; 23(1):5. PubMed ID: 34850297
[TBL] [Abstract][Full Text] [Related]
11. Prediction of the Oral Pharmacokinetics and Food Effects of Gabapentin Enacarbil Extended-Release Tablets Using Biorelevant Dissolution Tests.
Yamaguchi Ikeuchi S; Kambayashi A; Kojima H; Oku N; Asai T
Biol Pharm Bull; 2018; 41(11):1708-1715. PubMed ID: 30381671
[TBL] [Abstract][Full Text] [Related]
12. RP-HPLC analytical method development and optimization for quantification of donepezil hydrochloride in orally disintegrating tablet.
Liew KB; Peh KK; Fung Tan YT
Pak J Pharm Sci; 2013 Sep; 26(5):961-6. PubMed ID: 24035953
[TBL] [Abstract][Full Text] [Related]
13. Application of biorelevant saliva-based dissolution for optimisation of orally disintegrating formulations of felodipine.
Ali J; Zgair A; Hameed GS; Garnett MC; Roberts CJ; Burley JC; Gershkovich P
Int J Pharm; 2019 Jan; 555():228-236. PubMed ID: 30465852
[TBL] [Abstract][Full Text] [Related]
14. Dissolution Profile of Mefenamic Acid Solid Dosage Forms in Two Compendial and Biorelevant (FaSSIF) Media.
Nurhikmah W; Sumirtapura YC; Pamudji JS
Sci Pharm; 2016; 84(1):181-90. PubMed ID: 27110508
[TBL] [Abstract][Full Text] [Related]
15. New Approach for the Application of USP Apparatus 3 in Dissolution Tests: Case Studies of Three Antihypertensive Immediate-Release Tablets.
Espíndola B; Bortolon FF; Pinto JMO; Pezzini BR; Stulzer HK
AAPS PharmSciTech; 2018 Oct; 19(7):2866-2874. PubMed ID: 29934804
[TBL] [Abstract][Full Text] [Related]
16. Bilayer Tablet Dissolution Kinetics Based on a Degassing Cyclic Flow UV-Vis Spectroscopy with Chemometrics.
Otsuka Y; Ito A; Takahashi T; Matsumura S; Takeuchi M; Tanaka H
Chem Pharm Bull (Tokyo); 2019; 67(4):361-366. PubMed ID: 30930440
[TBL] [Abstract][Full Text] [Related]
17. Influence of dissolution media pH and USP1 basket speed on erosion and disintegration characteristics of immediate release metformin hydrochloride tablets.
Desai D; Wong B; Huang Y; Tang D; Hemenway J; Paruchuri S; Guo H; Hsieh D; Timmins P
Pharm Dev Technol; 2015; 20(5):540-5. PubMed ID: 24621340
[TBL] [Abstract][Full Text] [Related]
18. Use of PBPK Modeling To Evaluate the Performance of Dissolv It, a Biorelevant Dissolution Assay for Orally Inhaled Drug Products.
Hassoun M; Malmlöf M; Scheibelhofer O; Kumar A; Bansal S; Selg E; Nowenwik M; Gerde P; Radivojev S; Paudel A; Arora S; Forbes B
Mol Pharm; 2019 Mar; 16(3):1245-1254. PubMed ID: 30640475
[TBL] [Abstract][Full Text] [Related]
19. Investigation of the Dissolution Profile of Gliclazide Modified-Release Tablets Using Different Apparatuses and Dissolution Conditions.
Skripnik KKS; Riekes MK; Pezzini BR; Cardoso SG; Stulzer HK
AAPS PharmSciTech; 2017 Jul; 18(5):1785-1794. PubMed ID: 27800567
[TBL] [Abstract][Full Text] [Related]
20. Multivariate approaches for the development of quality control in-situ fiber optics dissolution methods for fixed-dose combination tablets.
Medendorp J; Colón I; Ryan T
Drug Dev Ind Pharm; 2019 Jun; 45(6):999-1008. PubMed ID: 30905176
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
